US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Azenta, Inc. - Common Stock (NQ:AZTA)

38.75 +4.27 (+12.38%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Azenta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Tenet Healthcare, Revvity, Avantor, Azenta, and Elanco Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea... 
Via StockStory
Topics Economy Government World Trade
News headline image
3 Reasons AZTA is Risky and 1 Stock to Buy Instead
Over the last six months, Azenta’s shares have sunk to $25.86, producing a disappointing 12% loss - a stark contrast to the S&P 500’s 6.6% gain. This was par... 
Via StockStory
Topics Stocks
News headline image
1 Small-Cap Stock to Research Further and 2 Facing Headwinds
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Azenta Inc (NASDAQ:AZTA) Reports Q1 FY2026 Earnings Miss, Shares Drop 4.3% ↗
Via Chartmill
Topics Earnings
News headline image
3 Stocks Under $50 with Warning Signs
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
News headline image
Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court... 
Via StockStory
Topics Government World Trade
News headline image
3 of Wall Street’s Favorite Stocks We’re Skeptical Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
News headline image
Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
News headline image
The Top 5 Analyst Questions From Azenta’s Q4 Earnings Call
Azenta’s fourth quarter saw a flat sales trajectory, with revenue slightly ahead of Wall Street estimates but non-GAAP profit in line with expectations. The market responded negatively, reflecting... 
Via StockStory
Topics Earnings
News headline image
1 Healthcare Stock with Promising Prospects and 2 Facing Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and... 
Via StockStory
Topics Stocks
News headline image
Cold Chain, High Stakes: A Deep Dive into Azenta’s (AZTA) Life Sciences Transformation
Date: February 5, 2026 Introduction In the high-stakes world of life sciences, the "cold chain" is the invisible backbone of modern medicine. From the development of mRNA vaccines to the emerging... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
Stocks making big moves yesterday: Azenta, FTAI Aviation, Reddit, Columbia Sportswear, and RenaissanceRe
Check out the companies making headlines yesterday: 
Via StockStory
Topics Artificial Intelligence
News headline image
AZTA Q4 Deep Dive: Operational Challenges and Turnaround Efforts Dominate Results
Life sciences company Azenta (NASDAQ:AZTA) reported Q4 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $148.6 million. Its non-GAAP profit of $0.14 per... 
Via StockStory
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Azenta (AZTA) Stock Trades Down, Here Is Why
Shares of life sciences company Azenta (NASDAQ:AZTA) fell 24.6% in the afternoon session after it reported mixed fourth-quarter results that failed to impress investors. 
Via StockStory
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Azenta (AZTA) Q1 2026 Earnings Call Transcript ↗
Azenta (AZTA) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Azenta’s (NASDAQ:AZTA) Q4 CY2025: Beats On Revenue
Life sciences company Azenta (NASDAQ:AZTA) reported Q4 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $148.6 million. Its non-GAAP profit of $0.14 per... 
Via StockStory
News headline image
Azenta (AZTA) To Report Earnings Tomorrow: Here Is What To Expect
Life sciences company Azenta (NASDAQ:AZTA) will be announcing earnings results this Wednesday before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Safe-and-Steady Stock with Solid Fundamentals and 2 We Ignore
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
Why Are Azenta (AZTA) Shares Soaring Today
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 7.3% in the afternoon session after Evercore ISI Group upgraded the company's rating to "Outperform" from "In-Line" and raised its price... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 High-Flying Stock with Impressive Fundamentals and 2 We Find Risky
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
News headline image
Azenta (AZTA): Buy, Sell, or Hold Post Q3 Earnings?
Azenta trades at $34.56 and has moved in lockstep with the market. Its shares have returned 12.3% over the last six months while the S&P 500 has gained 11.7%. 
Via StockStory
Topics Economy Stocks
News headline image
3 Overrated Stocks We Steer Clear Of
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
News headline image
Corporate Maneuvers: Buybacks Signal Confidence, Insider Trades Spark Scrutiny
In a dynamic period for the financial markets, several public companies are making headlines with significant corporate actions. Azenta Inc. (NASDAQ: AZTA) and Fabasoft AG (XTRA: FSY) have recently... 
Via MarketMinute
Topics Law Enforcement Regulatory Compliance
News headline image
Why a $5 Million Bet on Azenta Could Pay Off After a 70% Stock Slide ↗
A major earnings reset and fresh fund interest could mark a turning point for this formerly high-flying life-sciences stock. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Healthcare Stocks We’re Skeptical Of
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand,... 
Via StockStory
Topics Stocks
News headline image
Q3 Rundown: Azenta (NASDAQ:AZTA) Vs Other Drug Development Inputs & Services Stocks
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers. 
Via StockStory
News headline image
Why Azenta (AZTA) Stock Is Trading Up Today
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 4.2% in the afternoon session after a report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
AZTA Q3 Deep Dive: Operational Discipline and Product Strength Support Margin Expansion
Life sciences company Azenta (NASDAQ:AZTA) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 5.5% year on year to $159.2 million. Its non-GAAP profit of $0.19 per... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 Next >